Biolex Therapeutics, Inc. – Trademark Portfolio

Entity Type: 03

Biolex Therapeutics, Inc. holds 9 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 40 (Treatment & Processing) — 5 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 5 Nice Classification classes. The owner is based in Pittsboro, NC.

158 Credle Street

Pittsboro, NC 27312

9 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

Biolex Therapeutics, Inc.'s trademark portfolio spans 5 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

40
Treatment & Processing (5 filings)

Treatment of materials

42
Computer & Scientific (4 filings)

Scientific and technological services; industrial analysis and research services

5
Pharmaceuticals (4 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

1
Chemicals (3 filings)

Chemical products for industry, science, photography, agriculture, horticulture and forestry

11
Environmental Control (1 filing)

Apparatus for lighting, heating, steam generating, cooking, refrigerating, drying

Frequently Asked Questions

How many trademarks does Biolex Therapeutics, Inc. have?

Biolex Therapeutics, Inc. has 9 U.S. trademarks filed with the USPTO.

What trademark classes does Biolex Therapeutics, Inc. file in?

Biolex Therapeutics, Inc. files trademarks across 5 Nice Classification classes. The most active classes are Class 40 (Treatment & Processing), Class 42 (Computer & Scientific), Class 5 (Pharmaceuticals), Class 1 (Chemicals), Class 11 (Environmental Control). Class 40 covers treatment of materials.

What is Biolex Therapeutics, Inc.'s trademark registration success rate?

Biolex Therapeutics, Inc. has a 0% trademark registration rate, with 0 out of 9 resolved applications resulting in successful registration. Currently, 0 applications are pending review.